Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Public ClinicalTrials.gov record NCT05631574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)
Study identification
- NCT ID
- NCT05631574
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Enrollment
- 13 participants
Conditions and interventions
Conditions
- CRC
- Colorectal Cancer
- KRAS Mutation-Related Tumors
- NSCLC
- Non Small Cell Lung Cancer
- PDAC
- Pancreatic Cancer
- Refractory Cancer
- Relapsed Cancer
- Stage III Colorectal Cancer
- Stage III NSCLC
- Stage III Non-small Cell Lung Cancer
- Stage III Pancreatic Cancer
- Stage IV Colorectal Cancer
- Stage IV NSCLC
- Stage IV Non-small Cell Lung Cancer
- Stage IV Pancreatic Cancer
Interventions
- BMF-219 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2023
- Primary completion
- Jan 14, 2025
- Completion
- Jan 14, 2025
- Last update posted
- Feb 6, 2025
2023 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Treatment Centers of America - Phoenix | Goodyear | Arizona | 85338 | — |
| California Cancer Associates for Research and Excellence (cCARE) | Encinitas | California | 92024 | — |
| University of California, San Diego | La Jolla | California | 92037 | — |
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80237 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Cancer Treatment Centers of America - Atlanta | Atlanta | Georgia | 30269 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy | Chicago | Illinois | 60611 | — |
| Cancer Treatment Centers of America - Chicago | Zion | Illinois | 60099 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| NEXT Virginia | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05631574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05631574 live on ClinicalTrials.gov.